Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma.
View/ Open
Date
2022-01-24ICR Author
Author
Mohamed, AA
Gordon, A
Cartwright, E
Cunningham, D
Type
Journal Article
Metadata
Show full item recordAbstract
Oesophago-gastric adenocarcinoma remains a leading cause of cancer-related morbidity and mortality worldwide. Although there has been an enormous progress in the multimodality management of resectable oesophago-gastric adenocarcinoma, most patients still develop a recurrent disease that eventually becomes resistant to systemic therapy. Currently, there is no global consensus on the optimal multimodality approach and there are variations in accepted standards of care, ranging from preoperative chemoradiation to perioperative chemotherapy and, more recently, adjuvant immune checkpoint inhibitors. Ongoing clinical trials are aimed to directly compare multimodal treatment options as well as the additional benefit of targeted therapies and immunotherapies. Furthermore, our understanding of the molecular and genetic features of oesophago-gastric cancer has improved significantly over the last decade and these data may help inform the best approach for the individual patient, utilising biomarker selection and precision medicine.
Collections
Research team
Medicine (RMH Smith Cunningham)
Language
eng
Date accepted
2022-01-20
License start date
2022-01-24
Citation
Cancers, 2022, 14 (3)